CTOs on the Move

Xenocor

www.xenocor.com

 
Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.xenocor.com
  • 630, Komas Drive
    Salt Lake City, UT USA 84108
  • Phone: 844.936.6267

Executives

Name Title Contact Details

Similar Companies

Insys

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.

Santaris Pharma A/S USA

Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PRC

PRC is a global leader in AAC Solutions including for individuals with speech disorders. *This group does not provide official technical support.

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.